PSMB9 and nasopharyngeal carcinoma: There are currently clinical trials underway focusing on therapeutic vaccines, including a modified vaccinia Ankara-based vaccine targeting EBNA1 and LMP2 in patients with NPC in remission (clinical trial ID: NCT01256853).